Pfizer, Inc. (PFE) Receives Buy Rating from BMO Capital Markets
BMO Capital Markets reissued their buy rating on shares of Pfizer, Inc. (NYSE:PFE) in a research report released on Wednesday. They currently have a $37.00 target price on the biopharmaceutical company’s stock.
Several other equities research analysts also recently commented on PFE. Citigroup Inc. downgraded Pfizer from a neutral rating to a sell rating and dropped their target price for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. ValuEngine downgraded Pfizer from a buy rating to a hold rating in a report on Friday, June 2nd. Morgan Stanley reiterated a neutral rating and set a $35.00 target price (down from $38.00) on shares of Pfizer in a report on Monday, June 12th. Jefferies Group LLC reiterated a neutral rating and set a $34.00 target price on shares of Pfizer in a report on Friday, June 16th. Finally, BidaskClub upgraded Pfizer from a strong sell rating to a sell rating in a report on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $37.61.
Shares of Pfizer (NYSE PFE) opened at 33.99 on Wednesday. Pfizer has a one year low of $29.83 and a one year high of $34.81. The company has a 50-day moving average of $33.33 and a 200 day moving average of $33.48. The stock has a market capitalization of $202.15 billion, a price-to-earnings ratio of 24.86 and a beta of 1.00.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $0.64 EPS. Equities research analysts forecast that Pfizer will post $2.56 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.77%. Pfizer’s dividend payout ratio is currently 94.12%.
In related news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the transaction, the insider now owns 124,774 shares in the company, valued at approximately $4,242,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders have sold a total of 426,291 shares of company stock valued at $14,475,911 in the last 90 days. Insiders own 0.06% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Asset Planning Services Ltd. boosted its position in Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in Pfizer during the 2nd quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer during the 2nd quarter valued at approximately $103,000. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Finally, Orrstown Financial Services Inc. boosted its position in Pfizer by 23.0% during the 1st quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 612 shares during the period. Institutional investors and hedge funds own 69.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.